Get to Know Dr. David Bartlett
Surgical oncologist Dr. David Bartlett, a long-time pioneer in advancing the treatment of abdominal malignancies, was named chair of the Allegheny Health Network Cancer Institute in 2020.
Bartlett spent two decades at the nearby University of Pittsburgh Medical Center. He carved out a reputation as a visionary in both research and clinical practice, specializing in treating peritoneal mesothelioma.
Through the years, Bartlett played a leading role in refining the hyperthermic intraperitoneal chemoperfusion (HIPEC) procedure that is used so successfully today for several abdominal cancers. The procedure, combined with cytoreductive surgery, administers chemotherapeutic drugs directly to the peritoneal cavity.
Success with that combination has helped many patients with peritoneal mesothelioma live 10 years or more after being diagnosed, a dramatic improvement from two decades ago.
Bartlett also treats appendiceal, gastric, colon and ovarian cancer and has continued his research work, which includes gene therapy and the use of a laboratory altered version of the smallpox vaccine to fight cancer.
Specialties of Dr. David Bartlett
- Peritoneal mesothelioma
- Hyperthermic intraperitoneal chemoperfusion
- Ovarian cancer
- Appendiceal cancer
- Colon cancer
- Cytoreductive surgery
- Gene therapy
Dr. David Bartlett’s Experience and Medical Education
- Allegheny Health Network Cancer Institute
- University of Pittsburgh Medical Center
- National Cancer Institute
- MD Anderson Cancer Center (Fellowship)
- Memorial Sloan Kettering Cancer Center (Fellowship)
- Perelman School of Medicine, University of Pennsylvania (Residency)
- University of Texas School of Medicine (MD)
Awards and Other Recognitions
- Society of Surgical Oncology (President)
- Lifetime Achievement Award
- Healthgrades Honor Roll
- America’s Top Doctors
- America’s Top Doctors for Cancer
Clinical Trials Under Dr. David Bartlett
- Phase I clinical trial to determine the safest dosage level when using the combination of celecoxib, interferon alfa and rintatolimod and given with a DC vaccine for peritoneal surface malignancies.
- Phase I clinical trial to determine safe dosage levels of the drug oxaliplatin when delivered by hepatic perfusion for unresectable colorectal liver disease.
Administrative Role for Dr. David Bartlett
Bartlett intends to continue treating patients and breaking new ground in research, despite an ever-expanding administrative role at the Allegheny Health Network.
As chair of the network’s cancer institute, he will oversee a team of more than 200 physicians, 500 advanced-practice oncology professionals and the network’s oncology clinical trial and laboratory research programs.
Allegheny Health Network is expected to open an $80 million academic center in 2021 that will include a genomics lab and a precision medicine and immunotherapy program.
Bartlett is accustomed to juggling different roles. While at the University of Pittsburgh Medical Center, he served as vice chair for surgical oncology and gastrointestinal surgery services; director of the David C. Koch Regional Perfusion Cancer Therapy Center; and chief of surgery for UPMC Shadyside Hospital.
Publications of Dr. David Bartlett
- Kaltenmeier, C., et al. (2019, December 10). Time to Surgery and Colon Cancer Survival in the United States. Annals of Surgery.
- Kiran, K.K. et al. (2018, May 15). Together We Make a Difference. Gastrointestinal Oncology.
- Bartlett, D.L. (2008, May). HIPEC: The Complexities of Clinical Trials. Annals of Surgical Oncology.